OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear

761 Projects | 523 Researchers | $306,533,976 Invested

2024

Johns Hopkins University

Jeffrey Rothstein, MD, PhD

Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.

  • Funding Amount: $269,967
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: TDP-43
  • Status: Active

2024

FINGERS Brain Health Institute

Miia Kivipelto, MD, PhD

Strategic Collaborative Framework for developing and testing innovative combination therapies, biomarkers, and digital solutions for precision prevention of cognitive decline and Alzheimer’s Disease and Related Dementias (previously: FINGERS Brain Health Institute - ADDF Memorandum of Understanding Planning Grant)

  • Funding Amount: $218,375
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Vascular
  • Status: Active

2024

University College London

Simon Mead, MD, FRCP, PhD

Biomarker-driven phenotyping for Alzheimer's disease and related dementia

  • Funding Amount: $297,986
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Other
  • Status: Active

2023

Metro International Biotech

David Livingston, PhD

Nicotinamide Mononucleotide in Patients with Alzheimer's Disease

  • Funding Amount: $10,750,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2023

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA

MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimer’s Disease

  • Funding Amount: $1,900,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Mitochondria/Metabolic Function
  • Status: Active

2023

NeuroAge Therapeutics

Christin Glorioso, MD, PhD

A multi-omics brain aging test for tracking cognitive sharpness and risk of dementia

  • Funding Amount: $249,817
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Epigenetics
  • Status: Active

2023

Optina Diagnostics

Jean-Philippe Sylvestre, PEng, PhD

Clinical value evaluation of the awAIr(TM)-CAS test based on hyperspectral retinal imaging

  • Funding Amount: $1,523,500
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Other
  • Status: Active

2023

Virginia Commonwealth University

Shijun Zhang, PhD

Probing neuroinflammation in Alzheimer's with NLRP3 PET radiotracers

  • Funding Amount: $600,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Active

2023

Genuv Inc.

Sungho HAN

Preclinical study to explore the proof-of concept of trametinib at the lowest dose for the development of a disease-modifying treatment for Alzheimer’s disease

  • Funding Amount: $600,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuronal Regeneration and Repair
  • Status: Active

2023

GliaPharm SA

Pierre Magistretti, MD, PhD

IND-enabling studies for GliaPharm’s lead candidate to rescue hypometabolism in Alzheimer’s disease

  • Funding Amount: $4,262,019
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Active
View More